Piper Sandler analyst David Amsellem lowered the firm’s price target on Cara Therapeutics to $12 from $13 and keeps an Overweight rating on the shares post the Q2 report. The analyst cites a revised share count for the target drop but sees continued Korsuva demand growth.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on CARA:
- Cara Therapeutics Reports Second Quarter 2023 Financial Results
- Is CARA a Buy, Before Earnings?
- Cara Therapeutics appoints Boudreau to its board of directors
- Cara Therapeutics to Present at the Canaccord Genuity 43rd Annual Growth Conference
- Cara Therapeutics to Announce Second Quarter 2023 Financial Results on August 7, 2023